648 related articles for article (PubMed ID: 34887858)
1. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
2. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N
J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309
[TBL] [Abstract][Full Text] [Related]
3. Identification of specific prognostic markers for lung squamous cell carcinoma based on tumor progression, immune infiltration, and stem index.
Wu R; Ma R; Duan X; Zhang J; Li K; Yu L; Zhang M; Liu P; Wang C
Front Immunol; 2023; 14():1236444. PubMed ID: 37841237
[TBL] [Abstract][Full Text] [Related]
4. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
5. Significance of
Lin H; Wang J; Shi Q; Wu M
PeerJ; 2024; 12():e17338. PubMed ID: 38708353
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
[TBL] [Abstract][Full Text] [Related]
7. Clinically relevant immune subtypes based on alternative splicing landscape of immune-related genes for lung cancer advanced PPPM approach.
Li N; Jia W; Wang J; Shao Q; Feng X; Li Z; Sun W; Kang M; Hu D; Xing L; Zhan X
EPMA J; 2024 Jun; 15(2):345-373. PubMed ID: 38841624
[TBL] [Abstract][Full Text] [Related]
8. A robust signature associated with patient prognosis and tumor immune microenvironment based on immune-related genes in lung squamous cell carcinoma.
Zhou H; Zhang H; Shi M; Wang J; Huang Z; Shi J
Int Immunopharmacol; 2020 Nov; 88():106856. PubMed ID: 32777677
[TBL] [Abstract][Full Text] [Related]
9. Development and validation of an immune-related prognostic signature in lung adenocarcinoma.
Sun S; Guo W; Wang Z; Wang X; Zhang G; Zhang H; Li R; Gao Y; Qiu B; Tan F; Gao Y; Xue Q; Gao S; He J
Cancer Med; 2020 Aug; 9(16):5960-5975. PubMed ID: 32592319
[TBL] [Abstract][Full Text] [Related]
10. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
11. Distinct signatures of lung cancer types: aberrant mucin O-glycosylation and compromised immune response.
Lucchetta M; da Piedade I; Mounir M; Vabistsevits M; Terkelsen T; Papaleo E
BMC Cancer; 2019 Aug; 19(1):824. PubMed ID: 31429720
[TBL] [Abstract][Full Text] [Related]
12. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
[TBL] [Abstract][Full Text] [Related]
13. A gene expression-based immune signature for lung adenocarcinoma prognosis.
Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F
Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Zengin T; Önal-Süzek T
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analyses of a CD8
Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
[TBL] [Abstract][Full Text] [Related]
16. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
17. Four hub genes regulate tumor infiltration by immune cells, antitumor immunity in the tumor microenvironment, and survival outcomes in lung squamous cell carcinoma patients.
Zhang T; Yang H; Sun B; Yao F
Aging (Albany NY); 2021 Jan; 13(3):3819-3842. PubMed ID: 33428598
[TBL] [Abstract][Full Text] [Related]
18. Construction and validation of a cuproptosis-related lncRNA signature for the prediction of the prognosis of LUAD and LUSC.
Wang Y; Xiao X; Li Y
Sci Rep; 2023 Feb; 13(1):2477. PubMed ID: 36774418
[TBL] [Abstract][Full Text] [Related]
19. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
20. Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
Wei Q; Jiang X; Miao X; Zhang Y; Chen F; Zhang P
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11351-11368. PubMed ID: 37378675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]